EAM
Erste Asset Management Portfolio holdings
AUM
$11.9B
1-Year Return
22.95%
This Quarter Return
+1.67%
1 Year Return
+22.95%
3 Year Return
+112.82%
5 Year Return
+205.55%
10 Year Return
–
AUM
$4.46B
AUM Growth
-$31.4M
(-0.7%)
Cap. Flow
-$10.2M
Cap. Flow
% of AUM
-0.23%
Top 10 Holdings %
Top 10 Hldgs %
18.46%
Holding
958
New
11
Increased
191
Reduced
114
Closed
25
Top Buys
| 1 |
Nucor
NUE
|
$21.2M |
| 2 |
Fluence Energy
FLNC
|
$11.1M |
| 3 |
Stem
STEM
|
$9.17M |
| 4 |
Snowflake
SNOW
|
$7.16M |
| 5 |
Merck
MRK
|
$6.23M |
Top Sells
| 1 |
Enphase Energy
ENPH
|
$21.3M |
| 2 |
Target
TGT
|
$20.8M |
| 3 |
Brookfield Renewable
BEP
|
$16.4M |
| 4 |
Sarepta Therapeutics
SRPT
|
$11.8M |
| 5 |
NVIDIA
NVDA
|
$10.4M |
Sector Composition
| 1 | Technology | 29.44% |
| 2 | Healthcare | 20.57% |
| 3 | Consumer Discretionary | 11.4% |
| 4 | Financials | 9.12% |
| 5 | Industrials | 8.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
TWOU
501
DELISTED
2U, Inc.
TWOU
| $167K | ﹤0.01% |
869
| – | – |
|
502
CDW
CDW
$22B
| $167K | ﹤0.01% |
1,070
-230
| -18% | -$35.9K |
|
503
Grifois
GRFS
$6.88B
| $161K | ﹤0.01% |
27,056
| – | – |
|
|
INBX
504
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $152K | ﹤0.01% |
8,700
| – | – |
|
505
Kura Oncology
KURA
$707M
| $146K | ﹤0.01% |
11,000
| – | – |
|
506
Caribou Biosciences
CRBU
$169M
| $145K | ﹤0.01% |
13,900
| – | – |
|
507
Nektar Therapeutics
NKTR
$843M
| $142K | ﹤0.01% |
3,120
| – | – |
|
508
Instil Bio
TIL
$174M
| $139K | ﹤0.01% |
1,375
| – | – |
|
509
Suncor Energy
SU
$48.8B
| $136K | ﹤0.01% |
4,800
| – | – |
|
510
VanEck ChiNext ETF
CNXT
$38M
| $131K | ﹤0.01% |
4,400
| – | – |
|
|
NSTG
511
DELISTED
NanoString Technologies, Inc.
NSTG
| $126K | ﹤0.01% |
9,900
| – | – |
|
512
PVH
PVH
$4.07B
| $126K | ﹤0.01% |
2,710
| – | – |
|
513
Freeport-McMoran
FCX
$67B
| $126K | ﹤0.01% |
4,600
-26,000
| -85% | -$711K |
|
514
iShares Global Healthcare ETF
IXJ
$3.85B
| $109K | ﹤0.01% |
1,450
-125
| -8% | -$9.42K |
|
515
Verizon
VZ
$183B
| $108K | ﹤0.01% |
2,839
-77,254
| -96% | -$2.93M |
|
516
Seer Inc
SEER
$114M
| $104K | ﹤0.01% |
13,000
| – | – |
|
517
Codexis
CDXS
$221M
| $94.7K | ﹤0.01% |
15,500
| – | – |
|
518
C4 Therapeutics
CCCC
$193M
| $91.4K | ﹤0.01% |
10,700
| – | – |
|
519
Nkarta
NKTX
$151M
| $90.9K | ﹤0.01% |
7,200
| – | – |
|
520
Kodiak Sciences
KOD
$517M
| $85.9K | ﹤0.01% |
11,300
| – | – |
|
521
Atara Biotherapeutics
ATRA
$85.5M
| $79.9K | ﹤0.01% |
880
| – | – |
|
522
Warner Bros
WBD
$30.6B
| $71.9K | ﹤0.01% |
6,165
+508
| +9% | +$5.92K |
|
523
iShares Global Energy ETF
IXC
$1.8B
| $70.4K | ﹤0.01% |
2,111
| – | – |
|
|
TSVT
524
DELISTED
2seventy bio
TSVT
| $70.3K | ﹤0.01% |
4,999
| – | – |
|
525
Ambev
ABEV
$34.3B
| $62.3K | ﹤0.01% |
22,000
| – | – |
|